SecBot SecBot
8-K ·Filed Sep 1, 2026

MMED

MiniMed Group, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001628280-26-059699
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The U.S. growth acceleration to 13% (from ~1.5% last quarter) confirms the MiniMed Flex launch is driving a step-change in domestic market share. With guidance raised and a strong pipeline (MiniMed Fit, Vivera FCL, extended-wear sensor), the stock should re-rate higher. Monitor Q2 for sustained U.S. NPS growth and CGM attachment rate progression above 70%.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$22.42
T+0 close · Sep 1, 2026 · via day close
Latest settled
−11.65%
T+20 · $19.81 · next T+60 in 8d
Vs SPY
−12.83%
α at T+20
Latest observation
−16.40%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $22.42entry
  2. T+1 · 3mo ago +5.98%α +5.53% · $23.76
  3. T+5 · 2mo ago +1.52%α +1.44% · $22.76
  4. T+20 · 7w ago −11.65%α −12.83% · $19.81
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiniMed reported Q1 FY27 net sales of $843M (+16.6% YoY as reported, +15.8% organic), with U.S. growth accelerating to 13.1% and international up 18.1%. The company raised FY27 organic revenue growth guidance to ~10.5% from ~10%, while reaffirming ~16% adjusted EBITDA margin. GAAP EPS was $0.00, essentially breakeven vs a loss of -$0.08 a year ago, but this is a medical device company where the Street focuses on revenue growth and pipeline catalysts, not GAAP EPS.

Key Financial Metrics

EPS
$0.00
est $0.09 · -100.0%
Revenue
$843.0M
est $828.4M · +1.8% · +16.6% YoY
Rating
in line
Guidance
~10.5% organic growth
raised
Gross Margin
55.2%

Key Facts

  • Worldwide net sales of $843M grew 16.6% as reported and 15.8% organic
  • U.S. net sales grew 13.1% YoY, accelerating from 1.5% in Q4 FY26, driven by MiniMed Flex launch
  • U.S. New Pumps Sold grew over 20% YoY
  • FY27 organic revenue growth guidance raised to ~10.5% from ~10%
  • MiniMed Fit patch pump submitted to FDA; MiniMed Flex received CE Mark; Vivera FCL pivotal trial enrollment complete
  • GAAP net income attributable to the Company was approximately $0 (breakeven) vs a loss of $19M in the prior year period
  • GAAP EPS was $0.00 vs -$0.08 in Q1 FY26

Financial Impact

Q1 net sales of $843M, up 16.6% YoY; FY27 organic revenue guidance raised to ~10.5%

revenueguidancenew pump salesCGM attachment rate

Risk Factors

  • GAAP profitability remains near zero; adjusted EBITDA margin guidance of ~16% leaves limited margin of safety if growth decelerates
  • Extra week benefit (~4-6%) in Q1 will not repeat in subsequent quarters
  • Competitive pressure from Dexcom G7 and Tandem Mobi could slow U.S. market share gains

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-059699
Document: mmed-20260901.htm0001628280-26-059699
Document: 0001628280-26-059699-index-headers.html0001628280-26-059699
Document: 0001628280-26-059699-index.html0001628280-26-059699
Document: 0001628280-26-059699.txt0001628280-26-059699
8-K Data (Synthetic)0001628280-26-059699

Track record

25 reports on MMED

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 8-K Mixed 6/10 Entry $18.77 Now $18.65 −0.64% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $18.81 Now $18.65 −0.86% settles Dec 15
  3. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $16.71 Now $18.65 +11.61% settles Dec 7
  4. Oct 22, 202625d ago SC 13G Neutral 4/10 Entry $18.34 Now $18.65 +1.69% settles Nov 20
  5. Oct 16, 20264w ago SC 13G/A Neutral 4/10 Entry $17.79 to $18.65 Now $18.65 +4.83% ▲ +4.83% +8.30% vs SPY
  6. Oct 16, 20264w ago 8-K Neutral 6/10 Entry $17.49 to $17.99 Now $18.65 +6.63% ▲ +2.86% +4.02% vs SPY
  7. Oct 6, 20265w ago EFFECT Neutral 3/10 Entry $19.64 to $18.85 Now $18.65 −5.04% ▼ −4.02% −0.85% vs SPY
  8. Oct 1, 20266w ago 3 Neutral 2/10 Entry $19.70 to $18.28 Now $18.65 −5.33% ▼ −7.21% −5.40% vs SPY
  9. Sep 14, 20269w ago 425 Neutral 4/10 Entry $21.97 to $18.80 Now $18.65 −15.11% ▼ −14.43% −16.69% vs SPY
  10. Sep 14, 20269w ago 425 Neutral 4/10 Entry $21.97 to $18.80 Now $18.65 −15.11% ▼ −14.43% −16.69% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (10h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026